.svg)
Macuject is pleased to announce that we will run a pilot of our novel AMD platform at leading US optometry and ophthalmology partner sites during H1 2024.
With the support of ANDHealth+, this work will deliver valuable real-world clinical feedback, and generate the necessary data to commence the regulatory approval process with the FDA.